Amphastar Pharmaceuticals (AMPH) Profit After Tax (2013 - 2026)

Amphastar Pharmaceuticals' Profit After Tax history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 74.61% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $79.2 million (down 44.06% YoY), while the FY2025 annual figure was $98.1 million, down 38.51% from the prior year.
• Profit After Tax was $6.4 million for Q1 2026 at Amphastar Pharmaceuticals, down from $24.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $49.2 million in Q3 2023 to a low of $6.4 million in Q1 2026.
• Historically, Profit After Tax has averaged $29.0 million across 5 years, with a median of $26.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax surged 381.11% in 2022, then slumped 74.61% in 2026.
• A 5-year view of Profit After Tax shows it stood at $33.9 million in 2022, then advanced by 6.65% to $36.2 million in 2023, then climbed by 4.97% to $38.0 million in 2024, then slumped by 35.65% to $24.4 million in 2025, then tumbled by 73.72% to $6.4 million in 2026.
• The last three Profit After Tax figures came in at $6.4 million (Q1 2026), $24.4 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.